Cosmos Health Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenues of $17.1 million for the third quarter, a 37.8% increase from $12.4 million in the same period last year. For the nine months ended September 30, 2025, total revenue reached $45.6 million, up from $40.2 million in 2024. Despite this growth, the company recorded a net loss of $5.4 million for the quarter, compared to a loss of $2.2 million in the prior year, and a nine-month net loss of $9 million, up from $6.6 million in 2024. The increase in losses was attributed to non-cash charges related to the fair value of convertible notes and derivative liabilities.
The company’s operational metrics also reflected growth, with a notable increase in customer engagement. Cosmos Health expanded its distribution network, adding approximately 75 new pharmacies, and secured significant purchase orders for its proprietary nutraceutical brand, Sky Premium Life, particularly in the UAE. The company’s manufacturing subsidiary, CANA S.A., has also shown improved revenue and gross profit, contributing to the overall revenue increase. The total assets of Cosmos Health rose to $69.5 million as of September 30, 2025, compared to $54.3 million at the end of 2024, driven by increases in cash, accounts receivable, and inventory.
Strategically, Cosmos Health has been active in acquisitions and partnerships to bolster its market position. The company completed the acquisition of Cloudscreen, an AI-powered platform for drug repurposing, and has plans to expand its product offerings and distribution channels. The company also entered into a significant distribution agreement for its nutraceutical products in the UAE, which is expected to enhance revenue streams. Additionally, the company has been focusing on enhancing its manufacturing capabilities and expanding its product portfolio, including the introduction of new nutraceuticals and generics.
In terms of financial health, Cosmos Health's cash and restricted cash increased significantly to $4.6 million from $315,105 at the end of 2024, primarily due to financing activities, including the issuance of convertible notes. However, the company reported negative working capital of $430,029 and an accumulated deficit of $123 million, raising concerns about its ability to continue as a going concern. Management has outlined plans to secure additional financing and expand its product lines to address these challenges. The company is also exploring amendments to existing debt facilities to enhance liquidity and has resumed its At-the-Market sales program to bolster cash reserves.
Looking ahead, Cosmos Health aims to leverage its recent acquisitions and strategic partnerships to drive growth. The company plans to continue expanding its distribution network and product offerings while managing operational costs. However, the ongoing need for external financing and the potential impact of market conditions on its operations remain critical factors that could influence its future performance.
About Cosmos Health Inc.
Cosmos Health Inc. is a diversified global healthcare company specializing in the development, manufacturing, and distribution of pharmaceutical and nutraceutical products. Its core segments include generic medicines, innovative drugs, nutraceuticals, biocides, medical devices, and telehealth services. The company leverages proprietary brands, research & development, and strategic partnerships to serve markets across Europe and beyond, emphasizing innovation, cost-efficiency, and a vertically integrated business model.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.